HDAC inhibitors and immunotherapy; a double edged sword?

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Cancer cells exhibit pathological epigenetic modifications, driving tumorigenesis.
• Histone deacetylase (HDAC) inhibitors are established cancer therapeutics.
• Immunotherapy offers clinical benefits for specific cancer patients.

Purpose of the Study:

• To review the effects of HDAC inhibitors on tumor cells and immune cells.
• To explore the synergistic potential of HDAC inhibitors with immunotherapy.
• To discuss mechanisms and future applications of HDAC inhibitors in cancer immunotherapy.

Main Methods:

• Literature review of studies on HDAC inhibitors, cancer cells, and immune cells.
• Analysis of existing data on HDAC inhibitor effects on immune cell function.
• Synthesis of information on synergistic interactions and mechanisms.

Main Results:

• HDAC inhibitors impact cancer cell viability and biology.
• HDAC inhibitors may synergize with immunotherapy for tumor elimination.
• The direct effects of HDAC inhibitors on immune cells are complex and debated, with initial data suggesting immunosuppression, but newer findings challenging this view.

Conclusions:

• HDAC inhibitors represent a novel targeted therapy for cancer, potentially enhancing immunotherapy efficacy.
• Understanding the nuanced effects of HDAC inhibitors on immune cells is crucial for optimizing combination therapies.
• Future research should focus on elucidating mechanisms and clinical applications of HDAC inhibitors in cancer immunocombination therapy.